drugset / Trial / NCT02500784
Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease
Phase 2
Withdrawn
Palo Alto Veterans Institute for Research
Alzheimer's Association · collabMylan · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to test the effects of long-term therapeutic doses of formoterol, on a) cerebrospinal fluid (CSF) tau levels, and Amyloid Beta protein 40/42 levels in the CSF, and b) cognitive function in people with mild to moderate Alzheimer' Disease (AD).
Timeline
- Start
- 2023-01
- Primary completion
- 2025-04
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Formoterol | Other / unclassified | 20 ug | Inhaled |